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Abstract. Head and neck squamous cell carcinomas 
(HNSCCs) frequently invade the bones of the facial skeleton. 
Semaphorin 4D (Sema4D) is an axon guidance molecule 
produced by oligodendrocytes. Sema4D was also identified in 
the bone microenvironment and many cancer tissues including 
HNSCC. To date, however, the role of Sema4D in cancer-asso-
ciated bone disease is still unknown. This is the first study to 
demonstrate the role of Sema4D in bone invasion of cancer. In 
the clinical tissue samples of bone lesion of HNSCC, Sema4D 
was detected at high levels, and its expression was correlated 
with insulin-like growth factor-I (IGF-I) expression. In vitro 
experiments showed that IGF-I regulates Sema4D expression 
and Sema4D increased proliferation, migration and invasion 
in HNSCC cells. Sema4D also regulated the expression of 
receptor activator of nuclear factor κβ ligand (RANKL) in 
osteoblasts, and this stimulated osteoclastgenesis. Furthermore, 
knockdown of Sema4D in HNSCC cells inhibited tumor 
growth and decreased the number of osteoclasts in a mouse 
xenograft model. Taken together, IGF-I-driven production of 
Sema4D in HNSCCs promotes osteoclastogenesis and bone 
invasion.
Introduction
Head and neck squamous cell carcinomas (HNSCCs) arise 
from epithelia of the oral cavity, pharynx, larynx, nasal 
cavity or paranasal sinuses, and they frequently invade the 
surrounding bones that comprise the facial skeleton because 
of the anatomical proximity (1). The clinical importance of 
bone invasion of HNSCC includes a high morbidity rate and a 
worse prognosis. It is thus essential to control bone invasion in 
the treatment of HNSCC (1).
The progression of HNSCC cells from epithelia to bone 
induces the production of cancer-associated factors synthe-
sized by either HNSCC cells or stromal cells activated by 
HNSCC cells (2). These factors induce the expression of 
receptor activator of nuclear factor κβ ligand (RANKL) in the 
osteoblasts, which results in osteoclast activation and bone 
destruction. Bone destruction leads to the release of growth 
factors preserved in bone, including insulin-like growth factor-I 
(IGF-I) and transforming growth factor-β (TGF-β) (3,4). These 
growth factors promote HNSCC bone invasion and further 
increase the production of cancer-associated factors, which 
triggers a vicious circle (2).
Semaphorins are a large family of molecules containing 
a cysteine-rich sema domain. They were originally shown 
to regulate axonal growth cone guidance in the developing 
central nervous system (5-7). To date, >30 semaphorins have 
been identified and classified into eight subgroups based on 
their species of origin and sequence similarity. Semaphorin 
receptors, i.e., the plexins, also contain a sema domain. 
Nine known plexins, i.e., Plexin-A1 to -A4, -B1 to -B3, -C1, 
and -D1 are grouped according to their structure similarity. 
Semaphorin-plexin interactions were initially thought to 
be limited to the central nervous system, but these interac-
tions are now implicated widely in the non-nervous systems, 
i.e., the cardiovascular (8), endocrine (9), gastrointestinal (10), 
immune (11) and respiratory (12) systems.
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Semaphorin 4D (Sema4D) is an axon guidance molecule 
produced by oligodendrocytes (13). Sema4D is also expressed 
by T-lymphocytes and eosinophils and functions in the immune 
system (13). Sema4D was identified in the bone microenvi-
ronment, and shown to be expressed by osteoclasts that act 
through Plexin-B1 on osteoblasts to inhibit their differentia-
tion through inhibiting IGF-I signaling (14). Sema4D is also 
highly expressed in many cancer tissues including cancer of 
the prostate, colon, breast, lung and HNSCC (15). Moreover, 
Sema4D was recently reported to promote osteoclastogenesis 
and bone metastasis in breast cancer (7).
These findings prompted us to explore whether HNSCC 
cells could use Sema4D to invade bone. The results of our 
present study demonstrate that 1) a high amount of Sema4D 
was present in the tissue samples of bone lesions of HNSCC, 
and 2) the expression of Sema4D was correlated with IGF-I 
expression. we also observed that 3) HNSCC cell lines express 
high levels of Sema4D driven by IGF-I, and 4) Sema4D 
increases the proliferation, migration and invasion of HNSCC 
cells. Our results demonstrate that 5) osteoblasts produce 
RANKL in response to Sema4D, which activates osteoclasts, 
further stimulating bone resorption. Finally, we observed 
6) the inhibition of tumor growth and decreased numbers of 
osteoclasts in a mouse model of HSC-2 cells with knocked 
down Sema4D compared to controls.
Materials and methods
Clinical samples. All of the HNSCC patients whose cases 
were retrospectively examined herein were treated at the 
Department of Oral and Maxillofacial Surgery, Okayama 
University Hospital (Okayama, Japan) between 2000 and 2010, 
and the diagnosis was pathologically confirmed HNSCC (six 
cases of soft tissue HNSCC, include three cases of T4N0M0, 
two cases of T4N1M0 and a case of T4N2M0. Nine cases of 
HNSCC with jaw bone invasion include four cases of T4N0M0, 
two cases of T4N1M0 and three cases of T4N2M0). No patient 
had received chemotherapy or radiation therapy before surgery. 
The study was approved by the ethics committee of the 
Okayama University Graduate School of Medicine, Dentistry, 
and Pharmaceutical Sciences (protocol no. 1949), including 
the use of an advertisement poster in place of patient consent. 
written consent was not acquired for this retrospective study.
we had access to the patient records prior to the data 
anonymization. The surgically resected tissues were collected 
as part of the patients' routine care by the authors. All patient 
information was anonymized and de-identified prior to the 
analysis. The sections were deparaffinized and then autoclaved 
in 0.2% citrate buffer for 15 min for antigen retrieval. Sections 
were incubated with 3% hydrogen peroxide for 30 min to block 
endogenous peroxidase activity.
Primary rabbit anti-human Sema4D polyclonal IgG, rabbit 
anti-human Plexin-B1 polyclonal IgG, rabbit anti-human IGF-I 
polyclonal IgG and rabbit anti-human IGFI-R polyclonal IgG 
antibodies (Abcam, Cambridge, MA, USA) were used for 
immunohistochemisty analyses. The specimens were incu-
bated with a 1:100 dilution of the antibody overnight at 4˚C, 
followed by three washes with Tris-buffered saline (TBS). The 
slides were then treated with a streptoavidin-biotin complex 
(Envision System Labeled Polymer, horseradish peroxidase 
(HRP); Dako, Carpinteria, CA, USA) for 60 min at a dilu-
tion of 1:100. The immunoreaction was visualized using a 
3,3'-diaminobenzidine (DAB) substrate-chromogen solution 
(Dako Cytomation Liquid DAB Substrate Chromogen System, 
Dako). Finally, the sections were immersed in an ethanol 
and xylene bath and mounted for examination. Sections 
were photographed and the DAB density was detected using 
ImageJ (NIH, Bethesda, MD, USA). Thereafter, the threshold 
of density was set automatically and the α value (0-255) was 
calculated also by ImageJ software.
Cell culture and reagents. Human HNSCC cell lines HSC-2 
and SAS and bone marrow-derived stroma cell line ST-2 
cells were obtained from the Cell Engineering Division 
of RIKEN BioResource Center (Tsukuba, Ibaraki, Japan). 
Both cancer cell lines were cultured in Dulbecco's modified 
Eagle's medium/Ham's F-12 nutrient mixture (DMEM/F-12) 
supplemented with 10% fetal bovine serum (FBS). The bone 
marrow cells were isolated from 5-week-old male C57BL/6 
mice obtained from Charles River (Yokoyama, Japan).
Bone marrow cells was cultured in the α-modification of 
minimum essential medium (αΜΕΜ; Sigma, St. Louis, MO, 
USA) supplemented with 10% fetal calf serum (FCS) (Hyclone 
Laboratories, Logan, UT, USA) and penicillin/streptomycin 
solution in an atmosphere of 5% CO2/air at 37˚C. Linsitinib (an 
IGF-I receptor inhibitor), SCH772984 (an ERK inhibitor) and 
MK2206 (an AKT inhibitor) were purchased from MedChem 
Express (Princeton, NJ, USA). Primary mouse osteoblasts 
(i.e., osteoblasts from a cranial bone culture kit F-2) were 
purchased from Cosmo Bio (Tokyo, Japan) and cultured in 
αΜΕΜ supplemented with 10% FCS.
Immunoblot analysis. Cell monolayer cultures were rinsed 
with ice-cold phosphate-buffered saline (PBS) and lysed in 
an ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 
150 mM NaCl, 1% Triton X-100, 1% NP-40, 10 mM NaF, 
100 mM leupeptin, 2 mg/ml aprotinin and 1 mM phenylmethyl 
sulfonyl fluoride). Protein quantification was performed by 
Protein Assay System (Thermo Fisher Scientific, Waltham, 
MA, USA). Cell lysates containing 10 µg of total protein in 
the lysis buffer were electrophoresed in 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, 
and the proteins were then transferred to nylon membranes 
(Immobilon-P; Millipore, Bedford, MA, USA). The membranes 
were blocked with 2% non-fat dry milk in TBS overnight 
at 4˚C and then incubated with rabbit anti-human Sema4D 
polyclonal IgG, rabbit anti-human Plexin-B1 polyclonal IgG 
(Abcam) or rabbit anti-mouse RANKL polyclonal IgG (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) antibodies used at 
a 1:200 dilution. HRP-conjugate of goat anti-rabbit polyclonal 
IgG was used as the secondary antibody at a 1:1000 dilution 
(Amersham Biosciences, Buckinghamshire, UK). Bands were 
visualized by the ECL chemiluminescence detection method 
(RPN2109; Amersham Biosciences).
Cell proliferation. Cells were seeded at a density of 3x103 cells 
per well in a 96-well plate and cultured for 24 h. They were 
then cultured in the presence of recombinant human Sema4D 
(R&D Systems, Minneapolis, MN, USA). An MTS assay 
was performed to obtain a relative cell number after 48 h of 
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incubation under the experimental procedure specified by 
the manufacturer (Cell Titer 96 AQueous One Solution Cell 
Proliferation Assay; Promega, Madison, wI, USA).
Invasion and migration assay. we studied the invasion and 
migration of cells by using Boyden chambers with and without 
Matrigel® (BD Biosciences, Franklin Lakes, NJ, USA). Cells 
in the logarithmic growth phase were detached by trypsin-
EDTA, and 3x104 cells in medium without FBS were added 
to polycarbonate membranes (pore size 8.0 µm). Sema4D was 
added to the lower chamber, and the system was incubated at 
37˚C for 24 h in 5% CO2. After incubation and fixation, the cells 
on the upper side of the membrane were removed with a cotton 
swab and the remaining cells were stained with 2% Crystal 
Violet (Sigma). The number of stained cells on the lower side 
of the membrane in four microscopic fields was counted, and 
the average of cells in three wells was determined.
TRAP staining and osteoclast activity assay. Bone 
marrow macrophages (BMMs) were prepared as previ-
ously described (16). Bone marrow cells were isolated from 
5-week-old male C57BL/6 mice obtained from Charles 
River and cultured with 10 ng/ml of macrophage colony-
stimulating factor (M-CSF; R&D Systems) for 24 h, floating 
cells were collected and cultured with 30 ng/ml M-CSF for 
3 days. Thereafter, cells that were attached to the plates were 
collected as BMMs.
BMMs (4x104) were seeded on 48-well plates and cultured 
with 30 ng/ml M-CSF in the presence or absence of Sema4D 
(R&D Systems) and/or 50 ng/ml RANKL (Peprotech, 
London, UK) for 6 days. The medium was completely changed 
every 2 days. The cells were then fixed and stained for TRAP 
(Sigma), and the number of TRAP-positive multinucleated 
cells (nuclear number >3) in each well was counted.
For the osteoclast activity assay, BMMs (1x105) were seeded 
on hydroxyapatite-coated plates (Osteo Assay Surface 24-well 
plate, Corning, NY, USA) and cultured as above. The area 
of pits on the plates was quantified by ImageJ. For RANKL 
inhibitory assay, BMMs (1x105) were seeded on 24-well plates 
and cultured without RANKL with 30 ng/ml M-CSF in the 
presence or absence of Sema4D and osteoprotegerin (OPG; 
Peprotech) for 6 days. The number of TRAP-positive multi-
nucleated cells (nuclear number >3) in each well was counted.
Knockdown of Sema4D in HNSCC cells. we purchased 
Sema4D short hairpin RNAs (shRNAs) cloned into a 
pLKO.1-puro plasmid under the control of human phospho-
glycerate kinase eukaryotic promoter for stable expression 
(Mission® shRNA Plasmid DNA, SHCLND-NM_006378, 
Sigma) and scrambled sequence shRNA constructs (Mission 
Non-Target shRNA Control Vector, SHC002, Sigma). 
HNSCC cells are transfected with shRNA-pLKO.1-puro using 
Lipofectamine 3000® (Thermo Fisher Scientific) according to 
the manufacturer's instructions.
After 2 weeks in medium containing the selection antibi-
otic puromycin, cells stably expressing the shRNA were 
selected from transfected cultures. Sema4D knockdown was 
confirmed by performing an immunoblot analysis and evalu-
ated by using ImageJ. The five types of shRNA used were: 
shSema4D#1, CCGGGCCTGTGACTTGGTTTCTCTTCT 
CGAGA AGAGA A ACCA AGTCACAG G CT T T T TG; 
shSema4D#2, CCGGCGAACCAAAGATCGTCATCAAC 
TCGAGT TGATGACGATCT T TGGT TCGT T T T TG; 
shSema4D#3, CCGGGCCTGTGTTCTATGCACTCTTCT 





Bone xenograft model. All animal experiments were approved 
by the Institutional Animal Care and Use Committee of 
Okayama University. The bone xenograft model was prepared 
as previously described (17). Five-week-old male athymic mice 
(nu/nu) were obtained from CLEA Japan (Tokyo). HSC-2 cells, 
5x106 per mouse, were inoculated into the paraperiosteal tissue 
of the tibial metaphysis (17). Six mice per group were used.
Tumor sizes and body weights were measured weekly, 
and the former were recorded in cubic millimeters 
(length x width2/2). The animals were sacrificed at day 28, and 
the tumor tissues were removed and weighed.
Immunohistochemistry for xenograft tumor specimens. 
Paraffin blocks of specimens were cut at 4 µm thickness. 
Immunohistochemistry (IHC) was performed with rabbit 
Figure 1. Expression levels of Sema4D, Plexin-B1, IGF-I and IGF-IR in 
clinical HNSCC samples. (A) α values (0-255) calculated from DAB density 
in tumor samples (six cases of soft tissue HNSCC and nine cases of HNSCC 
with jaw bone invasion). **p<0.01. (B) Correlation coefficients showing 
the relationship between pairs of groups of Sema4D, Plexin-B1, IGF-I and 
IGF-IR.
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anti-human Sema4D polyclonal IgG, rabbit anti-human 
Plexin-B1 polyclonal IgG, rabbit anti-human IGF-I polyclonal 
IgG, rabbit anti-human IGFI-R polyclonal IgG, rabbit anti-
human Ki67 polyclonal IgG and rabbit anti-mouse CD31 
polyclonal IgG antibodies used at a 1:100 dilution (Abcam). 
Sections were incubated with the primary antibodies at 4˚C 
for 16 h, and visualized with the Envision system (Dako). The 
number of TRAP-positive multinucleated osteoclasts in three 
visual fields under a microscope (x200) were counted, and 
the osteoclast number per bone perimeter (per 100 mm) was 
calculated as previously described (18).
Statistical analysis. we analyzed the data (except those from 
the clinical samples) by using the unpaired Student's t-test 
for comparisons of two groups, and Fisher's protected least 
significant difference (Fisher's PLSD) for multiple group 
comparisons. Results are expressed as the mean ± SD. Values 
of p<0.05 were considered significant. The data from clinical 
samples were analyzed using the Mann-whitney U test because 
of the non-parametric distribution of data. The relationships 
between pairs of groups were analyzed by using the calculated 
correlation coefficient.
Results
Sema4D is highly expressed in the HNSCC tumors with bone 
invasion and correlates with IGF-I expression. we examined 
the expression of Sema4D in different HNSCC tumors, and 
found that its level was 2.1-fold higher in HNSCCs with 
bone invasion compared to HNSCCs without bone inva-
sion (p=0.0027) (Fig. 1A). Of note, Sema4D expression was 
significantly correlated with IGF-I expression (correlation 
coefficient: 0.52) (Fig. 1B).
Sema4D and Plexin-B1 are expressed in HNSCC cells in vitro. 
Since Sema4D was highly expressed in HNSCC tumors with 
bone invasion, we examined whether Sema4D was expressed 
in HNSCC cell lines HSC-2, HSC-3 and SAS in vitro. All 
three HNSCC cell lines exhibited weak Sema4D expression, 
but this expression was comparable to that of the Jurkat T cells 
used as the positive control for Sema4D (Fig. 2A).
Plexin-B1 was strongly expressed in all three HNSCC 
cell lines similarly to HUVEC cells, which were the positive 
control for Plexin-B1 (Fig. 2A). Noteworthy, IGF-I increased 
the expression of Sema4D by 2.1- and 1.5-fold in HSC-2 
and SAS cells, respectively (Fig. 2B). Moreover, Linsitinib 
(an IGF-IR inhibitor), SCH772984 (an ERK inhibitor) and 
MK2206 (an AKT inhibitor) suppressed IGF-I-induced 
Sema4D expression. Taken together, our findings demonstrate 
that Sema4D and Plexin-B1 were expressed in HNSCC cells 
and that Sema4D expression was regulated by IGF-IR down-
stream signaling including ERK and AKT. TGF-β did not 
increase Sema4D expression in HSC-2 or SAS cells (data not 
shown).
Figure 3. Effects of Sema4D on cellular activity of HSC-2 and SAS 
cells. (A and B) The MTS assay was performed to obtain the relative cell 
number. (C and D) Migration was studied by using Boyden chambers. 
(E and F) Invasion was studied using Boyden chambers with Matrigel®. All 
experiments were repeated three times. Data are the mean ± SD of triplicates 
from a typical experiment. *p<0.05.
Figure 2. Expression of Sema4D and Plexin-B1 in HNSCC cell lines. 
(A) Expression of Sema4D and Plexin-B1 in HSC-2, HSC-3 and SAS cells. 
Jurkat and HUVEC were the positive controls of Sema4D and Plexin-B1, 
respectively. (B) Expression of Sema4D and Plexin-B1 induced by IGF-I 
in HSC-2 and SAS cells. Cells were cultured in the presence or absence of 
IGF-I treated with Linsitinib, SCH772984 or MK2206 at the concentration 
of 1 µM. Similar results were obtained in at least 3 independent experiments.
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Sema4D upregulates HNSCC cellular activity. To examine 
the effect of Sema4D in vitro, we treated HNSCC cells 
with different concentrations of Sema4D and measured cell 
proliferation by MTS assay. with 100 ng/ml Sema4D, the 
proliferation was stimulated 1.5-fold and 1.3-fold (Fig. 3A 
and B) and the cell migration was enhanced 1.8-fold and 
2.7-fold in HSC-2 and SAS cells, respectively (Fig. 3C and D). 
with 100 ng/ml Sema4D, invasion was enhanced 2.6-fold and 
2.4-fold in HSC-2 and SAS cells, respectively (Fig. 3E and F).
Sema4D enhances osteoclastogenesis and bone resorptive 
activity. Since Sema4D increased proliferation of HNSCC cell 
lines, we next studied the effect of Sema4D on osteoclasts. 
BMMs were treated with Sema4D in the presence of M-CSF 
and RANKL for 6 days. At the concentration of 100 ng/ml, 
Sema4D increased the osteoclastogenesis by 1.4-fold and the 
osteolytic activity by 3.8-fold (Fig. 4A and B). Since Plexin-B1 
is known to be expressed in osteoblasts (14), we postulated 
that Sema4D enhances osteoclastogenesis through Plexin-B1 
on osteoblasts. To test this hypothesis, we treated ST-2 cells 
and primary mouse osteoblasts with Sema4D and then evalu-
ated the expression of RANKL by immunoblotting. As shown 
in Fig. 4C, RANKL expression was upregulated by 100 ng/ml 
Sema4D 1.5-fold in ST-2 cells, and was induced in primary 
mouse osteoblasts. To elucidate the role of RANKL in 
Sema4D-stimulated osteoclastogenesis, we treated BMMs with 
Sema4D without exogenous soluble RANKL with different 
concentrations of OPG. Fig. 4D shows that Sema4D promoted 
Figure 4. Effects of Sema4D on the formation and activity of osteoclasts in vitro. (A) BMMs were cultured with RANKL and M-CSF in the presence or absence 
of Sema4D. The number of TRAP-positive multinucleated cells in each well was counted. (B) BMMs were cultured on hydroxyapatite-coated plates. The area 
of pits on the plates was quantified by ImageJ. (C) ST-2 cells and primary mouse osteoblasts were cultured with Sema4D. RANKL expression was examined 
by immunoblot analysis. (D) BMMs were cultured without RANKL with M-CSF in the presence or absence of Sema4D (100 ng/ml) and OPG. The number of 
TRAP-positive multinucleated cells in each well was counted. All experiments were repeated three times. Data are the mean ± SD of triplicates from a typical 
experiment. *p<0.05.
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osteoclastogenesis without exogenous soluble RANKL and 
that OPG counteracted Sema4D-induced osteoclastogenesis, 
supporting the finding that Sema4D increased the RANKL 
expression in osteoblasts.
Knockdown of Sema4D inhibits bone invasion of xenograft 
HNSCC in athymic mice. To further investigate whether 
Sema4D production by HNSCC cells was responsible for bone 
invasion, we used shRNA to manipulate Sema4D expression 
in HNSCC cells. Sema4D shRNAs were purchased and trans-
fected into HSC-2 cells. Immunoblot analysis showed that 
the Sema4D expression in HSC-2 cells was knocked down by 
66.7% by shSema4D#4, which were thus used in the subse-
quent experiments (Fig. 5A).
Figure 5. Effect of knockdown of Sema4D on the growth of HSC-2 xenografts and osteoclastogenesis in athymic mice. (A) Knockdown of Sema4D with 
shRNA was confirmed by immunoblot analysis. (B and C) HSC-2 cells expressing the shControl or shSema4D were inoculated into the paraperiosteal tissue of 
the tibial metaphysis. Tumor volume and weight were recorded. *p<0.05. (D) IHC staining for Sema4D, Plexin-B1, IGF-I, IGF-IR, Ki-67 and CD31 in tumors 
from the HSC-2 expressing shControl or shSema4D. Sema4D, Plexin-B1, IGF-I, IGF-IR, CD31: x200 magnification. Ki67: x400 magnification. Ki67-positive 
and total numbers of cells were counted in 5 randomly selected areas at a magnification of x400. CD31-positive neovessels in each tumor were counted in 
the five most vascularized areas at a magnification of x200, and the numbers were averaged. Images shown are from a representative animal of each group. 
(E) Hematoxylin and eosin (H&E) and TRAP staining of tumor specimens from the HSC-2 expressing shControl or shSema4D. Magnification, x20. The 
number of TRAP-positive osteoclasts (arrow) in each group was counted. *p<0.05.
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In the animal experiment, the growth rate of xenograft 
tumors was decreased in Sema4D knockdown group compared 
to that of the control group (Fig. 5B). The tumor volumes at 
the end of the experiment (day 28) for the groups treated with 
shControl and shSema4D were 416.9±63.8 and 127.2±21.9 mm3, 
respectively, indicating an approximately 69.4% decrease in 
tumor growth rate in shSema4D-treated group. The end tumor 
weights at day 28 for the groups treated with shControl and 
shSema4D were 500.0±57.7 and 283.3±37.3 mg, respectively, 
indicating an approximately 43.4% decrease in the tumor 
growth rate for the shSema4D-treated group (Fig. 5C). These 
results suggest that knockdown of Sema4D effectively inhib-
ited xenograft tumor growth of HNSCC cells in athymic mice. 
Our IHC analysis of the tumor specimens showed lower level 
of Sema4D in the knockdown group, which is consistent with 
the immunoblot results (Fig. 5A and D). IHC staining with 
an anti-Ki67 antibody showed that the percentage of Ki67-
positive cancer cells in the groups treated with shControl 
and shSema4D were significantly decreased from 55.8±3.0 to 
15.2±5.6, respectively, representing a 72.3% decrease in cell 
proliferation (Fig. 5D). Vessel density in the groups treated 
with shControl and shSema4D, as shown by CD31-positive 
vessels, was 59.0±16.7 and 20.8±2.5, respectively, representing 
a 64.7% decrease in tumor angiogenesis (Fig. 5D). Knockdown 
of Sema4D exerted antitumor effects in HNSCC in in vivo 
experiments via the suppression of cancer cell proliferation 
and angiogenesis.
To determine whether Sema4D in HNSCC cells influences 
osteoclastogenesis in vivo, we evaluated the number of TRAP-
positive multinucleated osteoclasts in tumor specimens. As 
shown in Fig. 5E, the numbers of osteoclasts were greatly 
reduced in the shSema4D-treated group compared to the 
control group. The quantitative analysis demonstrated a 65.2% 
decrease in osteoclast formation following the Sema4D knock- 
down. Taken together, these results indicate that the expression 
of Sema4D in HNSCC is important for osteoclastogenesis and 
for bone invasion (Fig. 6).
Discussion
Previous research indicated that the axon guidance molecule 
Sema4D has an important role in cancer progression (19). 
Sema4D shed by HNSCC cells acts through Plexin-B1 on 
vascular endothelial cells to promote cell migration and tube 
formation, which promotes tumor angiogenesis (15). An 
immunohistochemical analysis of Sema4D in a large tumor 
sample collection revealed that Sema4D overexpression was 
present in 80% of the HNSCCs (15). Sema4D has been shown 
to act directly on breast (19-21) and ovarian (22) cancer cells, 
inducing invasion and metastasis.
The results of our present study demonstrate that both 
Sema4D and Plexin-B1 were expressed in HNSCC cell lines 
and that Sema4D increased cell proliferation, migration and 
invasion, suggesting that Sema4D shed by HNSCC cells acts 
through Plexin-B1 on HNSCC cells themselves in an auto-
crine manner. A prior study showed that Sema4D activates 
the small GTPase RhoA, which is related to cytoskeleton 
reorganization and focal adhesion formation (23). Moreover, 
Sema4D has also been shown to regulate PYK2 [a non-
receptor tyrosine kinase of the focal adhesion kinase (FAK) 
family] and modulate cell motility (24). Sema4D causes the 
AKT and MAPK phosphorylation (24,25), the signaling of 
which suppresses apoptosis and promotes cell multiplication, 
respectively. These findings suggest that Sema4D plays a 
direct role in disease progression of HNSCC, possibly through 
the signaling pathways mentioned above.
In the bone microenvironment, Sema4D expression in 
osteoclasts and Plexin-B1 expression in osteoblasts has been 
observed (14). To date, however, there has been no report 
describing the expression levels of Sema4D and Plexin-B1 in 
bone lesions of HNSCC. Our present findings demonstrate that 
a high expression of Sema4D is present in HNSCCs with bone 
invasion compared to those without bone invasion. Moreover, 
Sema4D expression was correlated with IGF-I expression in 
tumor tissue samples. These findings prompted us to investi-
gate whether IGF-I regulates Sema4D expression.
Of note, IGF-I greatly increased Sema4D expression in 
HNSCC cells, which is consistent with the results we obtained 
from the clinical samples. These data support our hypothesis 
that IGF-I released from bone regulates Sema4D expression 
and promotes bone invasion of HNSCC. In physiological 
conditions, IGF-I released from bone is resorbed by osteoclasts, 
although it was originally stored by osteoblasts, and it induces 
osteoblast differentiation. In contrast, Sema4D produced by 
osteoclasts inhibits osteoblast differentiation by inhibiting 
IGF-I signaling (14). In other words, osteoclasts control bone 
formation by osteoblasts based on a balance between Sema4D 
and IGF-I signaling. In osteolytic lesions of HNSCC, a high 
production of Sema4D by HNSCC cells ‘tips the scale’ of bone 
homeostasis in favor of resorption.
Mechanisms underlying the semaphorin enhancement of 
osteoclastogenesis have been reported (7,26,27). Mice with 
knock-out of Sema6D receptor plexin-A1 (plexin-A1-/-) have 
been phenotyped as having osteopetrosis due to the inhibition 
of osteoclastogenesis. In the presence of Sema6D, plexin-A1 
forms a complex with TREM2 (triggering receptor expressed 
on myeloid cells 2) and DAP12 (DNAX-activation protein 12), 
which promote osteoclastogenesis (26). Sema4D plays a role 
Figure 6. Role of Sema4D in bone invasion in HNSCC. IGF-I, which is 
released from bone, increases Sema4D secretion in HNSCC cells. Sema4D 
acts on HNSCC cells in an autocrine manner, which enhances cell activi-
ties. Sema4D also regulated RANKL expression in osteoblasts stimulating 
osteoclastgenesis.
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in functions of osteoclasts including spreading, adhesion, 
migration and resorption through β3 integrin subunit down-
stream signaling (27). Sema4D also promotes IL-8 expression 
in osteoblasts, which promotes osteoclastogenesis and bone 
metastasis of breast cancer (7).
In the present study, we observed that the RANKL expres-
sion in osteoblasts was upregulated by Sema4D. Strengthening 
this result, the OPG that was used to counteract RANKL 
successfully inhibited Sema4D-induced osteoclastogenesis. 
we also demonstrated that Sema4D shed by HNSCC cells 
was important for osteoclastogenesis in vivo and for bone 
invasion, using an animal model. However, we note here that 
activation of osteoclastogenesis by Sema4D might also be 
through the above-mentioned factor that has been implicated 
in a different type of cancer.
Bisphosphonates (28) and an anti-RANKL antibody (deno-
sumab) (29,30) are widely used to manage hypercalcemia of 
malignancy and skeletal metastases. These drugs target osteo-
clasts and do not have antitumor activity for cancer cells. The 
results presented here suggest that targeting Sema4D could be 
a novel treatment strategy for anti-osteoclastic and antitumor 
action in HNSCC therapy.
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